EBS Q2 2021 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$398M+0.7% YoY

Gross Profit

$121M30.4% margin

Operating Income

$15M3.6% margin

Net Income

$5M1.2% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

+15.9%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$97M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.4B

Stockholders' Equity

$1.5B

Cash & Equivalents

$448M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$398M	$395M	+0.7%
Gross Profit	$121M	$217M	-44.3%
Operating Income	$15M	$126M	-88.5%
Net Income	$5M	$93M	-95.0%

Revenue Segments

Contract Development And Manufacturing

$191M48%

Product

$181M46%

Contracts and Grants

$25M6%

Geographic Segments

Non-US

$236M59%

UNITED STATES

$161M41%